]>
IRCT20110918007582N2 IRCT 2018-12-01 Esfahan University of Medical Sciences Evaluation of Clonidine Therapeutic Effect Added to Usual Treatment in Refractory Obsessive –Compulsive Disorder Comparison of the efficacy of adding clonidine to SSRI and treating patients with SSRI alone in patients with treatment-resistant obsessive compulsive disorder 2018-12-22 anticipated 30 Complete https://irct.ir/trial/35429 interventional Randomization: Randomized, Blinding: Double blinded, Placebo: Used, Assignment: Parallel, Purpose: Treatment, Randomization description: Simple randomization using a random number table for people with obsessive-compulsive disorder. The random numbers and numbers are extracted by the computer and for allocation concealment unique code will be use, Blinding description: Patients do not know about their treatment, and medications are given in asymptomatic packagings to clinicians not to be aware about the pateint's treatment during the course. 3 obsessive compulsive disorder. Intervention 1: Intervention group: Clonidine tablets start with a dose of 0.1 mg once a night, and weekly (based on patient tolerance) 0.2 mg will add to reach a maximum of one mg per day. This dose is based on the administration of clonidine in other psychiatric disorders. Intervention 2: Control group: Will use placebo. Yes - There is a plan to make this available What will be shared: All data will be available. When: Access will begin immediately after the article is publish. To whom: Data will be available to all people. Conditions: All the necessary analyzes can be done and there are no specific conditions for access. Where to obtain: Send applicant to Dr. Akuchekian, email her at akuchekian@med.mui.ac.ir How to obtain: In the shortest time it will be available to the applicant. Comments:
public Shahla Akuchekian
Isfahan university
Isfahan Iran (Islamic Republic of) 5138663134 +98 31 1222 2127 akuchekian@med.mui.ac.ir Esfahan University of Medical Sciences scientific Shahla Akuchekian
Isfahan university
Isfahan Iran (Islamic Republic of) 5138663134 +98 31 1222 2127 akuchekian@med.mui.ac.ir Esfahan University of Medical Sciences Iran (Islamic Republic of) The presence of obsessive-compulsive disorder criteria based on DSM-V-TR Receive at least 12 weeks with a maximum dose of a serotonergic drug (SSRI or Clomipramine) Moderate to severe symptoms based on the obsessive-compulsive- Yerobyll-Brown scale (YBOCS) with a score of more than 16 Obtain informed consent from the patient No initial diagnosis of psychiatric disorders and mood disorder (bipolar or MDD) Absence of drug use or dependence There is no uncontrolled physical illness (such as diabetes, blood pressure, etc.) There is no previous history of Clonidine use Lack of pregnancy and lactation or planning for pregnancy during the study There is no seizure disorder No suicide attempt Not taking beta-blocker Failure to receive synchronous psychological intervention no limit no limit Both Cancellation of participation in the study at each stage of the research Pregnancy at each stage of the research F42 Obsessive-compulsive disorder Treatment - Drugs Treatment - Drugs Intervention group: Clonidine tablets start with a dose of 0.1 mg once a night, and weekly (based on patient tolerance) 0.2 mg will add to reach a maximum of one mg per day. This dose is based on the administration of clonidine in other psychiatric disorders Control group: Will use placebo OCD Scale changes with YBOCS questionnaire. Timepoint: Before the intervention and at the end of 4-8-12 weeks. Method of measurement: Yale Brown Obsessive-Compulsive Scale (YBOCS). Esfahan University of Medical Sciences Approved 2018-10-08 Isfahan University of Medical Sciense Isfahan Isfahan Isfehan Iran (Islamic Republic of)